Facebook-f Twitter Linkedin-in

Conference starts in 139 days

Main Menu

Principal sponsor workshops

The IATDMCT 2025 Congress features a range of dynamic sponsored lunch workshops, open to all delegates at no additional cost. Simply select your preferred sessions during the registration process.

If you have already registered and wish to attend a principal lunch workshop, please contact the congress organisers at iatdmct2025@expertevents.com.au.

Roche Industry Workshop No. 1
Monday 22 September 2025

Shaping the Future of Drug Testing & Diagnostics: Automation Meets Mass Spectrometry

Shaping the Future of Therapeutic Drug Monitoring & Drugs of Abuse Testing

Presented by:

YaYuan Lin
International Product Manager Mass Spectrometry at Roche Diagnostics International, Rotkreuz, Switzerland.

With a career spanning over two decades in the IVD industry, Ya Yuan Lin is the International Product Manager for Mass Spectrometry at Roche Diagnostics. Her enthusiasm for introducing groundbreaking technologies to diagnostic laboratories across the globe is palpable, particularly in her close work with R&D to develop innovative solutions for toxicology. Since joining Roche Diagnostics in 2004, Ya Yuan has cultivated a broad understanding of the business through roles in technical support, marketing, and business development, leading to her current focus on mass spectrometry since 2017.

Read bio

At this year’s IATDMCT congress, Roche will showcase its integrated approach to Therapeutic Drug Monitoring (TDM) and drug testing, combining mass spectrometry, Immunochemistry and Clinical Chemistry methods to deliver complementary, efficient, and scalable solutions. This session will highlight cutting-edge workflow optimization and advancements that enhance testing efficiency, standardization, and clinical decision-making. By integrating innovative technologies, Roche expands testing capabilities and precision diagnostics, reinforcing its commitment to innovation and leadership in drug testing and monitoring. Through continuous advancements in laboratory medicine, Roche is shaping the future of drug testing and diagnostics.

Pushing the Boundaries of Clinical Mass Spectrometry: The Future of Diagnostics with the Roche cobasⓇ i 601

Presented by:

Pieter Vermeersch
Professor of Medicine at the University of Leuven; clinical pathologist and head of special chemistry and mass spectrometry laboratory at the Clinical Department of Laboratory Medicine of the University Hospitals Leuven/Belgium

Pieter Vermeersch is a Professor of Medicine and Clinical Pathologist at the University Hospitals Leuven, Belgium, where he heads the special chemistry and mass spectrometry laboratory. His expertise spans therapeutic drug monitoring, toxicology, metabolic disorders and endocrinology, with a focus on cardiovascular and renal disease. Professor Vermeersch is dedicated to enhancing patient outcomes through the development of advanced mass spectrometry assays and improved test utilization. He also actively contributes to the field as the chairman of the EFLM Working Group Postanalytical Phase and a member of the EFLM Working Group Preanalytical Phase.

Read bio

Prof. Vermeersch will present findings from global multicenter evaluations on the cobasⓇ i 601 analyzer, a fully automated mass spectrometry system designed to improve workflow efficiency and reduce turn-around-time for LC-MS/MS analyses. The study assessed analytical performance, reliability, and practicality across different sets of analytes, including steroids, vitamins, immunosuppressants, antiepileptics, and antibiotics. Results demonstrated high throughput, precision, and strong agreement with current methods. Faster TAT for beta-lactams, voriconazole, and antiepileptics may enhance TDM and improve patient care, especially in critical care and emergency settings.

Roche Industry Workshop No. 2
Tuesday 23 September 2025

Advancing Standardization in Therapeutic Drug Monitoring:
From Metrology Concepts to Industry Solutions

ISD standardization – from early challenges towards a solution

Presented by:

Christoph Seger
PD Dr., FAMH Klinische Chemie; Labordiagnostic St. Gallen West AG, St. Gallen, Switzerland

Dr. Christoph Seger, FAMH, EuSpLM, is a habilitated chemist with 20+ years’ experience in laboratory medicine. Christoph Seger originally worked in university research and has held various management positions in university and private laboratories during his career. He currently holds a management board and CMO position in his Swiss laboratory business LDSGW. The major focus of his research activities is the development of new analytical methods for the fields of TDM and toxicology. These activities have led to 150+ publications and extensive lecturing activities. Christoph Seger served the IFCC as head of the joint IATDMCT/IFCC working group on immunosuppressants (WG-ID).

Read bio

Dr. Seger will discuss the evolution of immunosuppressant therapeutic drug monitoring (ISD-TDM) from early immunoassays, which lacked specificity and metrological traceability, to LC-MS/MS, which improved analyte specificity but faced challenges due to variations in local test developments. The introduction of commercial LC-MS/MS calibrators and the establishment of a JCTLM reference measurement procedure (RMP) for ISDs have significantly advanced standardization. While challenges remain, such as the need for primary reference materials and measurement services, ongoing efforts in RMP development and standardization are paving the way for full traceability and improved patient care.

Metrology in TDM: from academic concepts to IVD-industry support

Presented by:

Judith Taibon
PhD; Team Lead MS and Separation Technologies Roche Diagnostics GmbH, Penzberg, Germany

Since joining Roche Diagnostics in 2016, Dr. Taibon has been a team lead in the department of instrumental analytics at Roche Diagnostics. She is responsible for the development of reference measurement procedures used to standardize Roche's internal products. In her role, she works closely with internal and external stakeholders and is involved in various committees that focus on the implementation of traceability by IVD manufacturers.

Read bio

In this session, Dr. Taibon will discuss Roche’s commitment to advancing metrological traceability in therapeutic drug monitoring (TDM) through the development of reference measurement procedures (RMPs). When initiating development of a fully automated LC-MS/MS platform, the absence of suitable primary reference materials (PRM) and RMPs for many analytes posed a significant challenge. Recognizing the clinical importance of traceability, Roche has invested in developing RMPs across its portfolio in collaboration with academic institutions and clinical laboratories. These efforts have already led to multiple JCTLM-listed RMPs, with further developments for all Roche TDM analytes underway.

Disclaimer: cobasⓇ i 601 analyzer and IonifyⓇ Steroids 1 and Vitamin D reagent packs are CE-marked. Further IonifyⓇ reagents are still under development. These products are not cleared or available for use in the US. COBAS and IONIFY are trademarks of Roche. This study was funded by Roche Diagnostics GmbH, Mannheim.

Research was funded by Roche Diagnostics GmbH.

© IATDMCT2025.org

created by Aptly Web Design